drug_type
RELEVANT_DRUG
intervention_type
Biological (bispecific antibody)
drug_description
A bispecific antibody immunotherapy evaluated in a Phase 1 dose-escalation/expansion study for relapsed/refractory B-cell non-Hodgkin lymphoma. It is designed to bind two targets and redirect immune effector activity to malignant B cells. Dosed across 0.3-500 mg for up to 12 months. Specific antigens and effector mechanisms are not disclosed.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Not Reported
drug_mechanism_of_action
Bispecific antibody that links T cells to malignant B cells—binding CD3 on T cells and a B‑cell antigen—to form an immunologic synapse and trigger T‑cell–mediated cytotoxic killing; specific targets are not disclosed.
drug_name
DR-0201
nct_id_drug_ref
NCT06392477